Olaparib, rucaparib, niraparib and talazoparib are four PARP inhibitors that have been approved by the FDA for the treatment of germline BRCA-mutated breast or ovarian cancers (Plummer et al., 2005; Evers et al., 2008; Sandhu et al., 2010; Shen et al., 2013). This evidence concerns the gene PARP1 and ovarian carcinoma.